THERAPY DOSSIER · th-f4f56adcdcce

BCN057

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 29394953 ↗2018Reported benefit

BCN057 induces intestinal stem cell repair and mitigates radiation-induced intestinal injury.

MouseRadiationC57BL/6J, plus Lgr5-eGFP-IRES-CreERT2 and Rosa26 reporter linesMalen = Minimum n = 25 per group for survival; n = 10 per group for…Subcutaneous90 mg/kg body weight, 12 mg/mL in 30 per cent Captisol give…First dose 24 h after irradiation; a first dose delayed to 72 h was ineffective

Model: Radiation-induced gastrointestinal syndrome after abdominal irradiation of 14 to 16 Gy, or 14.5 Gy partial body irradiation with 40 per cent bone marrow shielding

BCN057 started 24 h after lethal abdominal irradiation rescued Lgr5 positive intestinal stem cells, restored epithelial integrity and improved survival, without radioprotecting colon tumour tissue.

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…